Back to School: How biopharma can reboot drug development. Access exclusive analysis here
UBS Securities analyst David Crossen lowered his
sales estimates for 1995 to $50 million from $60 million,
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury